The Story Behind the Dose

Balancing the Equation

I actually came to medical writing from the opposite side of the equation, the writing side, yet somehow ended up in the same place around the life sciences.

I did my PhD in Philosophy of Language, believe it or not, studying logic sequents associated with semantics and meta-ethical reasoning and assertions. I then started matching up how these assertions corroborated with what we know from neuroscience and cognition, which, coupled with a previous medical writing internship I’d already had at Novartis, later flung me into the world of pharmacometrics instead!

A Front-Row Seat into MIDD

I say medical writing, strictly I was more of a medical journalist at Novartis Pharma AG, writing articles about it’s modelling and simulation department, as they worked on projects like Xolair.

It was there that I was first introduced to the intricacies of Model-Informed Drug Development (MIDD), how complex pharmacokinetic and pharmacodynamic processes can be not only be expressed through differential mathematics, but also be used to simulate clinical outcomes and narrow down drug candidates long before millions are ever invested in clinical trials.

The Inevitable Apprenticeship

While I was refining my analytical skills during my doctoral research at the University of Birmingham, I also had the slightly unfair advantage of certain family connections. It turns out one of the industry’s leading minds in pharmacometrics at the time was my father, Dr. Phil Lowe, former Executive Director of Pharmacometrics at Novartis Pharma AG.

Under his guidance, I learned all about ADME, NONMEM, Compartmental Models, Binding Affinity, Allometry, popPK, PBPK, Half-Life, Goodness-of-fit, Inter-individual variability…(goes on for some time)…which soon culminated in me joining him when he retired and founded It’s all in the Dose Ltd!

Diving into pharmaceuticals

When Dad founded It’s all in the Dose Ltd in 2018, it was originally a way to keep his expertise active in the pharmacometrics world. I joined as a co-director and medical writer, applying all I’d learned first into Malaria research, and, when Covid later hit in 2020, into monoclonal antibodies, modelling adjacent patent litigation (expert witnessing), and, later, temporary contracts in domains like promotional med comms (lots of ABPI code), and healthcare & cosmetics adjacent copywriting.

The primary focus of It’s all in the Dose Ltd, however, remained publishing support of pharmacometrics manuscripts, something which traditional med comms agencies often struggle to work synergistically with, in comparison to their usual, clinical trial dominated world of p-values, AEs, DDIs and HRQoL metrics.

Passing the Torch

Dad later decided that he wanted to actually retire, finally, and so the Ltd company was officially closed in 2025, endorsing my continuation of the business as a sole trader under the same name.

I now run It’s all in the Dose assuming full ownership of the business and run the consultancy independently.

My work now spans the full spectrum of MIDD publishing, regulatory checks, and healthcare marketing. I support pharmacometricians, biotech teams, CROs, and regulated‑sector marketers who need clarity, accuracy, and an understanding of persuasive arguments, someone who understands the industry, and doesn’t need maths lessons to see what’s going on.

Beyond the Screen

Based in the West Midlands, I work with remote teams worldwide, from U.S. health-tech startups to European biotech firms. However, if your project requires a face-to-face deep dive, I am always within driving range (or a flight away) for those critical strategy meetings.